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The technical feasibility of renal transplantation was estab-
lished from the identical-twin experience in the 1950's [1]. The 
way in which these transplantations in the absence of an 
immunologic barrier contributed to the long and complex 
history of this field has been described in other reviews [2. 31. 
The next and more difficult task was to develop techniques to 
prevent the rejection that followed transplantation when donors 
and recipients were not genetically identical. 
Although total-body irradiation permitted occasional suc-
cesses in the face of genetic disparity [4], the emergence of 
renal transplantation as a practical undertaking depended on the 
development of chemical immunosuppression. The first step 
toward this objective has often been overlooked, partly because 
its full significance was not perceived for more than a decade. 
In 1951, Billingham, Krohn, and Medawar ]51 and Morgan [6] 
showed in rabbits that the rejection of primary skin grafts was 
significantly delayed by steroid therapy. Krohn 17] later proved 
that even second-set rejections in presensitized recipients could 
be favorably modified. 
An equally important development was made possible by 
Hitchings and Elion [8. 9], who recognized the immunosuppres-
sive properties of 6-mercaptopurine. Using this new drug. 
Schwartz and Dameshek ]10. 11] demonstrated that rejection of 
rodent skin grafts could be mitigated. The work was promptly 
confirmed [12]. Caine [13] and other workers showed the same 
rejection-modifying effect after kidney transplantation in dogs. 
and witbin a year the 6-mercaptopurine derivative, azathio-
prine, became available for evaluation [9, 14]. 
It soon became obvious that the purine analogues were 
incompletely effective. Their true value was impossible to 
assess in the canine model, since optimal care of immunosup-
pressed recipients was not feasible in a kennel environment. 
Evolution of techniques of chemical immunosuppression to 
prevent or reverse rejection of whole organs was dependent 
upon observations after the technically simple procedure of 
renal tntnsplantation in human recipients. 
DOllhle-drug regimens 
The immunosuppressive protocols that have been developed 
with and for human renal transplantation are summarized in 
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Table 1, exclusive of the historically important trials with total-
body irradiation that were carried out in Boston in the late 
1950's [4J. Because the first genuinely promising drug, azathio-
prine, proved to be effective only on rare occasions when given 
alone [15], the "modern" era was not entered until it was 
realized in 1962 and early 1963 that azathioprine and prednisone 
had an additive (or possibly synergistic) effect. With this drug 
combination, it was shown that rejection was a reversible 
process, and that the vigor of immunosuppression could often 
be lightened in some cases with the passage of time [16]. By the 
autumn of 1963, reports were published from four centers 
describing how azathioprine and prednisone could be used 
together [16-19]. It was of historical interest that Goodwin et al 
[20] had recognized at an earlier time and from an isolated 
observation that rejection might be a reversible process. Good-
win's patient was a young woman whose deteriorating graft 
function was temporarily improved when steroids were added 
to the base therapy with cyclophosphamide; the patient died of 
infection 144 days postoperatively. 
At the outset, our policy was to begin therapy after renal 
transplantation with azathioprine, and to add high doses of 
prednisone with the first signs of rejection r 16]. Because it was 
rare to escape rejection, even after transplantation from closely 
related donors, our recommendation soon became to begin 
treatment with both drugs immediately after transplantation, 
with a gradual subsequent reduction of the prednisone [21]. 
Sueh "double-drug therapy" has been the most commonly used 
immunosuppression throughout the world for almost 20 years. 
The impetus given to clinical renal transplantation by double 
drug therapy was great. Although clinical kidney transplanta-
tion had been attempted sporadically between 1936 and 1962 
(summarized by Groth [2]), the results had been so discouraging 
that most of these efforts had been discontinued. Early in 1963, 
there were less than ten clinical transplantation centers in the 
world, of which only five were active. With the advent of 
double drug therapy, new programs were started later in 1963 at 
the University of Minnesota (by William Kelly and Richard 
Lillehei), The Cleveland Clinic (by Wilhelm KoHl and Ralph 
Straffon), and in several other university centers. John Najar-
ian, then working in San Francisco and subsequently in Minne-
sota, was one of the important new figures to enter into the field 
in the summer of 1964. The proliferation of centers then and 
later was overwhelming (Los Angeles has 13 certified centers). 
With these massive efforts, it did not take long to appreciate the 
limitations as well as the value of double drug therapy. 
With transplantation from consanguineous donors under dou-
ble drug treatment, chronic renal graft function became achicv-
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Year described 
II Azathioprine Agents 19~n:l:~ported Boston Place fneffectiv-eK-d-ange~:::ienc~~- ~ - - \-Azathioprine-steroids 1963 [16-19] Denver, Richmond, \ 
Boston, Suboptimal I 
\ 
Edinborough \ 
• Thoracic duct drainage as adjunct 1963 [30]- Stockholm Nuisance: requires 20 to 30 days pretreatmerlt 
Thymectomy as adjunct 1963 [21, 35] Denver Unproven value i 
') Splenectomy as adjunct 1963 [21, 35] Denver No longer necessary 
ALG as adjunct 1966 [27] Denver Suboptimal 
Cyclophosphamide substitute for 1970 [29] Denver No advantage except for patients with 
azathioprine azathioprine toxicity I 
Total lymphoid irradiation 1979 [33, 34] Palo Alto, Minneapolis Dangerous; extensive preparation; not quicklt 
reversible \ 
Cyclosporine alone 1978-1979 [44. 45] Cambridge Suboptimal . 
Cyclosporine-steroids 1980 [46, 47J Denver Under evaluation \ 
• It w", "01 re,lired :::"0" '''" iii" pretro"~I"1 fot J 10 4 ;II~It;;f~I;;;;:;;;;Ip"nl;tion w" , n<c,,,,,, condition [3 i f~K . .. j 
able almost immediately in more than two thirds of the cases probably not be widely used in renal transpiant~tion b~~ause of 
[21,22]. However, during the first year after cadaveric renal its inconvenience, and the difficulty of reversing its effects in 
transplantation, the graft loss was high, and in multicenter the event of a complication from immunosuppression. 
compilations it has been about 50%, even in recent times [23, Two decades ago, thymectomy and splenectomy were intro-
24]. With the increased and wiser use of dialysis for fall-back duced as adjuncts to drug therapy [21, 35 J. Thymectomy did not 
maintenance in the event of uncontrollable rejection, patient have a demonstrable benefit and was abandoned, but a number 
mortality has gone down [25]. But the morbidity of chronic of recent randomized trials have supported the value ofsplenec-
immunosuppression (particularly with high-dose steroid thera- tomy. Our opinion is that in the new era ushered in with 
py) has been well recognized, even after ostensibly "success- cyclosporine (see later), splenectomy will no longer be needed. 
ful" operations [26]. The recognized need for better therapy 
prompted a number of deviations from the original formulas. 
Triple-drug therapy and other modifications 
Between 1963 and 1979, a number of modifications of, or 
additions to, the original double drug therapy were introduced 
(Table 1). The most promising approach was by lymphoid 
depletion with antilymphocyte globulin (ALG) [27]. Usually, 
the ALG was given intramuscularly or intravenously as a 
temporary supplement to azathioprine and prednisone during 
the first few weeks or months postoperatively. The greatest 
experience with this kind of treatment has been reported by 
Najarian et al [28]. More recently. ALG has had encouraging 
trials as an emergency agent, administered for the specific 
indication of a diagnosed rejection. "Triple-drug therapy" has 
been the second most commonly used immunosuppression. A 
theoretically important detail was the demonstration that cyclo-
phosphamide could be freely substituted for azathioprine [29]. 
This was of interest because cyclophosphamide has been 
thought to selectively affect antibody-producing B cells. Be-
cause the results were not improved, the use of cyc1ophospha-
. mide has been limited as a first line drug. 
The results of I-year graft survival after cadaveric renal 
transplantation under triple drug therapy (compared to that with 
-azathioprine-prednisone) were improved in most but not all 
centers in which trials were conducted. After the discontinu-
ance of ALG. there has been a moderately high rate of delayed 
rejection. The alternative of temporary lymphoid depletion with 
thoracic duct drainage (TDD) [30] in the preparation of patients 
for cadaveric renal transplantation [31] has proved to have the 
same disadvantage [32]. Lymphoid depletion by total lymphoid 
irradiation (TLI) for conditioning before grafting [33, 34] will 
Typing and transfusion 
There was wide-spread discontent with all techniques of 
immunosuppression available from 1963 to 1978. Many kidney 
transplant surgeons attempted to provide a more advantageous 
biologic environment for the grafts by exploiting developments 
in tissue typing and matching, or by systematically conditioning 
prospective renal recipients with preoperative blood transfu-
sions. The former efforts yielded disappointing results after 
cadaveric kidney transplantation [23, 24J probably because the 
genetic complexity of the histocompatibility system was too 
great to permit effective matching of nonrelated individuals. 
The latter practice of conditioning by transfusion has allowed 
an increased success rate in those patients not accidentally 
sensitized during their preparation [36]. The improved statistics 
with transfusion were explained in part by the weeding out from 
candidacy of those patients whose antibody responses dis-
closed them to be strong immune reactors. The consequence 
was the ability to treat a smaller number of recipients more 
successfully. However, for expansion of renal transplantation 
services, it was necessary to hope for better immunosuppres-
sive drugs. This did not seem a realistic possibility until the 
advent of cyclosporine. 
The cyclosporine era 
The fungus extract cyclosporine was discovered and charac-
terized biochemically by scientists at the Sandoz Corporation. 
Basel, Switzerland. Borel et al [37, 38] showed it to depress 
humoral and cellular immunity in mice, rats. and guinea pigs 
without the bone marrow depression which had frequently 
limited the doses of azathioprine and cyclophosphamide. Borel 
et al [37, 38] reported the unusual effectiveness of cyclosporine 
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Table 2. Cadaveric graft and patient survival in first cyc1osporine trial, from December 1979 to September 1980 
First grafts (57 in 57 
patients) 
Retransplants (10 in 9 
patients) 
Survival of the 66 patients 
At (, mo 
48 (84,2%) 
6 (60%) 
58 (87.9%) 
At 12 mo 
45 (79%) 
6 (60%) 
57 (86.4%) 
in preventing or delaying rejection of mouse skin homografts, 
and analogous observations soon followed about the protection 
of a variety of whole organs in several animal species [39-43]. 
Cyc1osporine was first used in 1978 in patients by CaIne et al 
[44, 45J. That experience led to the recommendation that no 
other drug be routinely administered. When the drug became 
available to us in 1979, we soon realized that cyclosporine 
should be combined with steroid therapy from the outset [46, 
47]. However, the steroid component with the latter new 
version of double drug therapy was much smaller than it was 
with azathioprine and prednisone. Although this was a learning 
experience with this drug combination, the I-year kidney 
survival after primary cadaver transplantation was 79% [47] 
(Table 2). 
The subsequent fate of grafts in these first-phase patients is 
summarized in Table 2. The 1- and 2-year primary graft 
survivals were 79 and 75.4% in a series of 57 cases. Of the 45 
primary cadaveric recipients who still bore their functioning 
grafts at the end of a year, 39 (68.4% of the original 57) are still 
free of dialysis on their original transplants with followups of 
2V4 to almost 3 years. Thirteen (22.8%) of the 57 recipients were 
switched to azathioprine from 4 months to 2 years after 
transplantation. Seven of the 13 grafts are still functioning. 
Rejection was common after the change [47]. 
In this pilot experience, 9 other patients underwent 10 
cadaveric retransplantations after rejecting 1 to 3 previous 
grafts from months to years earlier under conventional immuno-
suppression. Six of the transplants were left at the end of the 
year, and all 6 are still functioning after 27 to 34 months (Table 
2). 
The patient mortality in these learning trials was too high 
(Table 2). Nine (13.6%) of these first 66 patients died in the first 
year, often of over-immunosuppression in futile and unwise 
efforts to retain badly rejecting kidneys or because offailure to 
distinguish the difference between nephrotoxicity and rejection 
[47]. During the second postoperative year, an additional pa-
tient with normal renal function died of a dissecting aortic 
aneurysm, giving a 2-year mortality of 10/66 (15.2%). During the 
third postoperative year, 4 more patients died, one with normal 
function who had a pulmonary embolus after a hip replacement. 
The other 3 died following return to chronic hemodialysis after 
their grafts were rejected. Cardiac complications caused 2 of 
these 3 deaths, and the third patient died of a perirectal abscess 
with a supralevator extension. Fifty-two (78.8%) of the original 
66 patients are still living after 2 V4 to 3 years, and 45 are dialysis 
free. 
The first United States trials were at the University of 
Colorado [46, 47J and at the Peter Bent Brigham Hospital, 
Boston [48]. In the latter center, where cyclosporine was used 
alone and limited to the first 2 postoperative months. the results 
were disappointing [48J. Similar disillusionment was reported 
---- --- -- --------
At 18 mo At 24 mo 
----------
44 (77.2%) 
6 (60%) 
57 (86.4%) 
43 (75.4%) 
6 (60%) 
At 25 to 
36 mo 
39 (68.4%) 
6 (60%) 
52 (78.!l%) 
by Sweny et al from London, combining cyclosporine with 
cytotoxic drugs [49]. Subsequent trials in Houston [SO], Minne-
apolis [51], and at a later period in the Boston experience 
(unpublished) have verified the value of the cyclosporine-
steroid combination. Caine et al [52], using steroids for the 
specific indication of rejection, have reported 85% I-year 
cadaveric graft survival, and results about 10% below this have 
been obtained with the same approach in a collaborative 
European center trial [53]. 
The value of experience with cyclosporine-steroid therapy 
was evident in our second wave trials of cadaveric transplanta-
tion begun in March 1981. During 1981, 38 more patients 
received primary cadaveric homografts under treatment with 
cyclosporine and steroids. With a minimum followup of 11 to 20 
months, 35 (92.1%) of these 38 patients still have adequately 
functioning first grafts (Table 3). During the same period, 32 
other patients were treated with conventional azathioprine-
prednisone management, the majority of whom were partici-
pants in a randomized control trial. The I-year graft survival in 
the conventional group was 15/32 (49.9%). The divergence in 
results (Table 3) was so great that the randomized trial had to be 
discontinued. 
Of great interest was a further series of 30 cadaveric retrans-
plantations in 29 patients carried out in 1981, for which follow-
ups of almost 1 year to 1 % years are available (Table 3). The 1-
year graft survival was 76.6% in spite of the inclusion of 8 
recipients whose preoperative sera had widely reacting T-warm 
antibodies. Twenty (69%) of these 29 recipients still are dialy-
sis-free. A randomized control trial was not carried out because 
of the historically poor performance of retransplanted kidneys 
[54,55], but the results (Table 3) have been more than twice as 
good as those achieved at this same institution (University of 
Pittsburgh) during the preceding 3 years. The good results 
achievable with retransplantation have added an extra incentive 
to avoid over-immunosuppression with the first kidney if there 
are unusual difficulties with rejection, since now there is such 
an excellent prognosis for a second effort. 
The I-year mortality in the 1981 Pittsburgh cadaveric series 
(all cyclosporine cases plus conventional therapy) was 2 in 99 
(2%). The first death of a cyclosporine-treated patient was from 
a myocardial infarction 2 weeks after transplantation; he had a. 
functioning kidney. The second death was of a patient who had . 
rejected a kidney under azathioprine-steroid therapy. She died 
after 9 '/2 months postoperatively, 3 months after returning to 
chronic hemodialysis. An additional cyclosporine-treated pa-
tient with good renal function died 1 V2 years after retransplan-
tation of a ruptured abdominal aneurysm. 
The incidence of lymphoma in the cyclosporine trials has 
been watched with interest. A total of 136 recipients were given 
primary or secondary cadaveric renal grafts in 1980 and in 1981. 
Two (1.5%) developed lymphomas with features which have 
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Table 3. Cadaveric graft and patient survival in second cyclosporine (and control) trial (1981) 
----
----------
At 3 mo At 6 mo At 9 mo At 11 mo At 11 to 21 mo 
Primary grafts with 36 (94.7%) 35 (92.1%) 35 (92.1%) 35 (92.1%) 35 (92.1%) 
cyclosporine-steroids 
(N = 38) 
Primary grafts with 22 (68.8%) 17 (53.1%) 16 (50%) 15 (46.9%) 14 (43.8%) 
azathioprine-steroids 
(N = 32) 
Retransplants with 24 (80%) 23 (76.6%) 23 (76.6%) 23 (76.6%) 20 (66.7%)" 
cyclosporine-steroids 
(N = 29 patients) 
Survival in all 99 patients" 98 98 98 97 96 (97%) 
" Two deaths after 2 weeks and 18 months were with functioning grafts (one each in the cyclosporine and retransplantation series) and were 
caused by myocardial infarction and ruptured abdominal aneurysm. The third patient (azathioprine series) was anephnic and died of 
gastrointestinal hemorrhage 9'/2 months after transplantation. 
b Two of the 3 late graft losses were from chronic rejection after 12 and 13 months; the third was from death (ruptured aneurysm) after 18 months. 
been described elsewhere [47, 56]. One of the lymphomas was 
an incidental autopsy finding in a patient who died of Pneumo-
cystis carinii pneumonitis, and the other caused a small bowel 
perforation which was treated with resection. The latter patient 
is well 14 months later. A third patient with a perforated small 
bowel had a lymphoproliferative mass which was not thought to 
be a lymphoma [47]. She is well 2 1/2 years after intestinal 
resection. Thus, there have been no deaths attributable to 
lymphoma. There have been no examples of de novo epithelial 
tumors. 
Future prospects 
It has become clear that cyclosporine will make possible the 
expansion of renal transplantation with a greater emphasis on 
the use of cadaveric donors than in the past. The results 
described above from our cyclosporine experience in 1980 and 
1981 were obtained with random or nearly random donor-
recipient matching, and for the most part without systematic 
preoperative recipient transfusion. The early behavior and later 
durability of these cadaveric kidneys has suggested that tissue 
matching will playa less prominent role in future transplanta-
tion practices than was envisioned in the past. It is likely that 
the systematic preoperative preparation of recipients with 
blood transfusions will be less widely practiced, since the 
potential hazards of recipient sensitization and antibody forma-
tion may be unnecessary penalties. With the ability to use 
smaller doses of steroids, the pool of acceptable recipients is 
apt to expand and to include more diabetics, older patients, and 
others who are currently considered to be at high risk. It is 
noteworthy that 17 of the patients included in the 1980 and 1981 
experience (10 cyclosporine, 7 azathioprine) had type [ diabe-
tes; in this group there have been no deaths and 16 of the 17 are 
now dialysis-free. The cardiovascular complications which 
. were responsible for most of the deaths after 1 year further 
reflected the fact that many high-risk patients were already 
being included in these trials. The good rate of success both 
with primary and secondary cadaveric transplantation will be 
an inducement to minimize the use of living related donors, and 
this latter practice will undoubtedly become increasingly 
obsolete. 
As new teams begin using cyclosporine it will be important to 
avoid the unrealistic expectations about early convalescence 
that could be engendered by the high success rates that have 
already been achieved after cadaveric renal transplantations. In 
a recent analysis of 42 consecutive cadaveric renal recipients 
treated by us [56], only a third had a completely uneventful 
recovery. Of the remainder, most developed rejection, which 
usually could be reversed readily with augmented steroid 
therapy. In every case, the differential diagnosis that required 
evaluation was rejection versus nephrotoxicity from cyclospor-
ine. Fortunately, the complication of nephrotoxicity usually has 
promptly reversed with the reduction of cyclosporine doses, 
and as a last resort a change from cyclosporine to azathioprine 
can be made, but at a significant risk of subsequent rejection 
[57]. 
Most of the other side effects of cyclosporine have not been 
serious, including gum hyperplasia, tremor, regional flushing, 
or vague abdominal discomfort just after drug ingestion, and the 
development of breast fibroadenomas in women. Hepatotoxic-
ity has been seen in about one fifth of the patients [46, 58], but 
this rarely has been serious enough in renal recipients to 
necessitate a change to azathioprine. 
Lymphomas can be expected to develop with cyclosporine, 
just as has been documented with other forms of immunosup-
pression [59, 60]. However, the actual incidence may not be 
greater than it was with past forms of immunosuppression. The 
most accurate way of assessing the risk oflymphomas would be 
per month of immunosuppression, a kind of computation which 
would take into account the greater success rate with cyclo-
sporine-steroids and the reSUlting need for continuing therapy. 
The conclusion that epithelial tumors will be less common than 
they are with conventional immunosuppression must be consid-
ered tentative, but the freedom to date from the epithelial 
tumors, which under conventional immunosuppression account 
for about three fourths of the de novo neoplasms [60], has been 
noteworthy to date. As experience with cyclosporine has 
accumulated worldwide, the specter of this drug being a spec-
tacular tumor-producer has receded . 
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